ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1878

Cognitive Manifestations of Fibromyalgia and Lupus

Robert S. Katz and Frank Leavitt, Rush University Medical Center, Chicago, IL

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Cognitive dysfunction, fibromyalgia and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Fibromyalgia and Soft Tissue Disorders

Session Type: Abstract Submissions (ACR)

Background/Purpose: Similar cognitive complaints for patients with fibromyalgia and systemic lupus erythematosus (SLE) have been reported; however, inherently different deficits can share superficial similarities. The major purpose of this study is to determine if the two syndromes have deficits in cognitive functioning in common as measured by the new Mental Clutter Scale.

Methods: The Mental Clutter Scale is a new 16 item scales that focuses on 8 dimensions of the tradition cognitive skills such as memory and concentration, and 8 dimensions of disturbed mental clarity such as cluttered thinking and mental fog.    The measure was administered to 52 patients who met ACR criteria for fibromyalgia and 35 patients who met ACR criteria for Lupus.   The classification criterion for cognitive dysfunction was the upper boundary of the 95% confidence interval (CI) of the normative sample. This score provided prevalence rates of cognitive dysfunction in the two samples.

Results: The two groups were predominantly female (81.5% vs. 82.9%0), with those in the fibromyalgia group significantly older [mean (±SE) age (49.0 ± 12.7 vs. 32.2.3± 10.6 p<0.001)].  Cognitive dysfunction was present in 63.5% (33/52) of the sample with FMS and in 28.6% (10/35) of the sample with Lupus.  The differences were significant (p<0.001).   Both the traditional cognitive symptoms (52.7± 10.0 vs. 32.2± 10.6; p<0.004) and the disturbance in mental clarity (45.5 ± 15.5 vs. 30.6± 10.7; p<0.01) were more pronounced  in fibromyalgia.  Endorsement of the 16 subscales is shown in Table 1.  As can be seen, patients with FMS report significantly higher severity on 5 of 8 cognitive scales, and 7 of 8 mental clarity scales.

Conclusion:   The cognitive findings suggest that there is considerable difference in the cognitive functioning of people with fibromyalgia and Lupus.  The majority of patients with FMS report cognitive dysfunction; whereas only a minority of patients with lupus report cognitive dysfunction.  Among those reporting cognitive dysfunction, cognitive deficits are more pronounced in FMS.  Fog like features as measured by the mental clarity scale are more prominent in fibromyalgia, providing strong support for the notion of fibrofog.  Fog like features play less of a role in lupus, providing weak support for the notion of  brain fog in most lupus patients.



Disclosure:

R. S. Katz,
None;

F. Leavitt,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cognitive-manifestations-of-fibromyalgia-and-lupus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology